Drug
Lanreotide Autogel
Lanreotide Autogel: highest development phase Phase 3, developed by Ipsen. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lanreotide Autogel® NCT02493517 | Phase 3 | Acromegaly |
| Lanreotide autogel 120 mg NCT02651987 | Phase 2 | Pancreatic Tumours |
Latest
No recent events.
Follow Lanreotide Autogel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.